Minocycline 1‐year therapy in multiple‐system‐atrophy: Effect on clinical symptoms and [11C] (R)‐PK11195 PET (MEMSA‐trial)
Identifieur interne : 000E63 ( Main/Corpus ); précédent : 000E62; suivant : 000E64Minocycline 1‐year therapy in multiple‐system‐atrophy: Effect on clinical symptoms and [11C] (R)‐PK11195 PET (MEMSA‐trial)
Auteurs : Richard Dodel ; Annika Spottke ; Alexander Gerhard ; Alexander Reuss ; Sylvia Reinecker ; Nicole Schimke ; Claudia Trenkwalder ; Friederike Sixel-Döring ; Birgit Herting ; Christoph Kamm ; Thomas Gasser ; Martin Sawires ; Felix Geser ; Martin Köllensperger ; Klaus Seppi ; Manja Kloss ; Martin Krause ; Christine Daniels ; Günther Deuschl ; Silke Böttger ; Markus Naumann ; Axel Lipp ; Doreen Gruber ; Andreas Kupsch ; Yansheng Du ; Federico Turkheimer ; David J. Brooks ; Thomas Klockgether ; Werner Poewe ; Gregor Wenning ; Carmen Schade-Brittinger ; Wolfgang H. Oertel ; Karla EggertSource :
- Movement Disorders [ 0885-3185 ] ; 2010-01-15.
English descriptors
- KwdEn :
Abstract
The aim of the study was to investigate the efficacy of the antibiotic minocycline as a drug treatment in patients with Multiple‐System‐Atrophy Parkinson‐type (MSA‐P). Sixty‐three patients were randomized to minocycline 200 mg/d (n = 32) or a matching placebo (n = 31). The primary outcome variable was the change in the value of the motor score of the Unified Multiple‐System‐Atrophy Rating‐Scale (UMSARSII) from baseline to 48 weeks. Secondary outcome variables included subscores and individual Parkinsonian symptoms as determined by the UMSARS and the Unified‐Parkinson's‐Disease Rating‐Scale (UPDRS). Health‐related quality of life (HrQoL) was assessed using the EQ‐5D and SF‐12. “Progression rate” was assumed to be reflected in the change in motor function over 48 weeks. At 24 weeks and 48 weeks of follow‐up, there was a significant deterioration in motor scores in both groups, but neither the change in UMSARSII nor in UPDRSIII differed significantly between treatment groups, i.e. “progression rate” was considered to be similar in both treatment arms. HrQoL did not differ among the two treatment arms. In a small subgroup of patients (n = 8; minocycline = 3, placebo = 5)[11C](R)‐PK11195‐PET was performed. The three patients in the minocycline group had an attenuated mean increase in microglial activation as compared to the placebo group (P = 0.07) and in two of them individually showed decreased [11C](R)‐PK11195 binding actually decreased. These preliminary PET‐data suggest that minocycline may interfere with microglial activation. The relevance of this observation requires further investigation. This prospective, 48 week, randomized, double‐blind, multinational study failed to show a clinical effect of minocycline on symptom severity as assessed by clinical motor function. © 2009 Movement Disorder Society
Url:
DOI: 10.1002/mds.22732
Links to Exploration step
ISTEX:7E3C331E554F887479122609783881EAE1EEE31DLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Minocycline 1‐year therapy in multiple‐system‐atrophy: Effect on clinical symptoms and [11C] (R)‐PK11195 PET (MEMSA‐trial)</title><author><name sortKey="Dodel, Richard" sort="Dodel, Richard" uniqKey="Dodel R" first="Richard" last="Dodel">Richard Dodel</name><affiliation><mods:affiliation>Department of Neurology, Philipps‐University of Marburg, Germany</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, University of Bonn, Germany</mods:affiliation></affiliation></author><author><name sortKey="Spottke, Annika" sort="Spottke, Annika" uniqKey="Spottke A" first="Annika" last="Spottke">Annika Spottke</name><affiliation><mods:affiliation>Department of Neurology, University of Bonn, Germany</mods:affiliation></affiliation></author><author><name sortKey="Gerhard, Alexander" sort="Gerhard, Alexander" uniqKey="Gerhard A" first="Alexander" last="Gerhard">Alexander Gerhard</name><affiliation><mods:affiliation>Wolfson Molecular Imaging Centre, The University of Manchester, United Kingdom</mods:affiliation></affiliation><affiliation><mods:affiliation>IMRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College; London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Reuss, Alexander" sort="Reuss, Alexander" uniqKey="Reuss A" first="Alexander" last="Reuss">Alexander Reuss</name><affiliation><mods:affiliation>Coordinating Center for Clinical Trials, Philipps‐University of Marburg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Reinecker, Sylvia" sort="Reinecker, Sylvia" uniqKey="Reinecker S" first="Sylvia" last="Reinecker">Sylvia Reinecker</name><affiliation><mods:affiliation>Coordinating Center for Clinical Trials, Philipps‐University of Marburg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Schimke, Nicole" sort="Schimke, Nicole" uniqKey="Schimke N" first="Nicole" last="Schimke">Nicole Schimke</name><affiliation><mods:affiliation>Department of Neurology, Philipps‐University of Marburg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Trenkwalder, Claudia" sort="Trenkwalder, Claudia" uniqKey="Trenkwalder C" first="Claudia" last="Trenkwalder">Claudia Trenkwalder</name><affiliation><mods:affiliation>Paracelsus‐Elena‐Clinic Kassel, Germany</mods:affiliation></affiliation></author><author><name sortKey="Sixel Ring, Friederike" sort="Sixel Ring, Friederike" uniqKey="Sixel Ring F" first="Friederike" last="Sixel-Döring">Friederike Sixel-Döring</name><affiliation><mods:affiliation>Paracelsus‐Elena‐Clinic Kassel, Germany</mods:affiliation></affiliation></author><author><name sortKey="Herting, Birgit" sort="Herting, Birgit" uniqKey="Herting B" first="Birgit" last="Herting">Birgit Herting</name><affiliation><mods:affiliation>Department of Neurology, Dresden University of Technology, Germany</mods:affiliation></affiliation></author><author><name sortKey="Kamm, Christoph" sort="Kamm, Christoph" uniqKey="Kamm C" first="Christoph" last="Kamm">Christoph Kamm</name><affiliation><mods:affiliation>Hertie‐Institute, University of Tübingen, Germany</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, University of Rostock, Germany</mods:affiliation></affiliation></author><author><name sortKey="Gasser, Thomas" sort="Gasser, Thomas" uniqKey="Gasser T" first="Thomas" last="Gasser">Thomas Gasser</name><affiliation><mods:affiliation>Hertie‐Institute, University of Tübingen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Sawires, Martin" sort="Sawires, Martin" uniqKey="Sawires M" first="Martin" last="Sawires">Martin Sawires</name><affiliation><mods:affiliation>Department of Neurology, Medical University of Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="Geser, Felix" sort="Geser, Felix" uniqKey="Geser F" first="Felix" last="Geser">Felix Geser</name><affiliation><mods:affiliation>Department of Neurology, Medical University of Innsbruck, Austria</mods:affiliation></affiliation><affiliation><mods:affiliation>European MSA Study Group, Innsbruck Medical University, Austria</mods:affiliation></affiliation></author><author><name sortKey="Kollensperger, Martin" sort="Kollensperger, Martin" uniqKey="Kollensperger M" first="Martin" last="Köllensperger">Martin Köllensperger</name><affiliation><mods:affiliation>Department of Neurology, Medical University of Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="Seppi, Klaus" sort="Seppi, Klaus" uniqKey="Seppi K" first="Klaus" last="Seppi">Klaus Seppi</name><affiliation><mods:affiliation>Department of Neurology, Medical University of Innsbruck, Austria</mods:affiliation></affiliation><affiliation><mods:affiliation>European MSA Study Group, Innsbruck Medical University, Austria</mods:affiliation></affiliation></author><author><name sortKey="Kloss, Manja" sort="Kloss, Manja" uniqKey="Kloss M" first="Manja" last="Kloss">Manja Kloss</name><affiliation><mods:affiliation>Department of Neurology, University of Heidelberg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Krause, Martin" sort="Krause, Martin" uniqKey="Krause M" first="Martin" last="Krause">Martin Krause</name><affiliation><mods:affiliation>Department of Neurology, University of Heidelberg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Daniels, Christine" sort="Daniels, Christine" uniqKey="Daniels C" first="Christine" last="Daniels">Christine Daniels</name><affiliation><mods:affiliation>Department of Neurology, University of Kiel, Germany</mods:affiliation></affiliation></author><author><name sortKey="Deuschl, Gunther" sort="Deuschl, Gunther" uniqKey="Deuschl G" first="Günther" last="Deuschl">Günther Deuschl</name><affiliation><mods:affiliation>Department of Neurology, University of Kiel, Germany</mods:affiliation></affiliation></author><author><name sortKey="Bottger, Silke" sort="Bottger, Silke" uniqKey="Bottger S" first="Silke" last="Böttger">Silke Böttger</name><affiliation><mods:affiliation>Department of Neurology, University of Würzburg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Naumann, Markus" sort="Naumann, Markus" uniqKey="Naumann M" first="Markus" last="Naumann">Markus Naumann</name><affiliation><mods:affiliation>Department of Neurology, University of Würzburg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Lipp, Axel" sort="Lipp, Axel" uniqKey="Lipp A" first="Axel" last="Lipp">Axel Lipp</name><affiliation><mods:affiliation>Wolfson Molecular Imaging Centre, The University of Manchester, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Gruber, Doreen" sort="Gruber, Doreen" uniqKey="Gruber D" first="Doreen" last="Gruber">Doreen Gruber</name><affiliation><mods:affiliation>Department of Neurology, University of Berlin, Germany</mods:affiliation></affiliation></author><author><name sortKey="Kupsch, Andreas" sort="Kupsch, Andreas" uniqKey="Kupsch A" first="Andreas" last="Kupsch">Andreas Kupsch</name><affiliation><mods:affiliation>Department of Neurology, University of Berlin, Germany</mods:affiliation></affiliation></author><author><name sortKey="Du, Yansheng" sort="Du, Yansheng" uniqKey="Du Y" first="Yansheng" last="Du">Yansheng Du</name><affiliation><mods:affiliation>Department of Neurology, Indiana University Medical School, Indianapolis, Indiana, USA</mods:affiliation></affiliation></author><author><name sortKey="Turkheimer, Federico" sort="Turkheimer, Federico" uniqKey="Turkheimer F" first="Federico" last="Turkheimer">Federico Turkheimer</name><affiliation><mods:affiliation>IMRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College; London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Brooks, David J" sort="Brooks, David J" uniqKey="Brooks D" first="David J." last="Brooks">David J. Brooks</name><affiliation><mods:affiliation>IMRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College; London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Klockgether, Thomas" sort="Klockgether, Thomas" uniqKey="Klockgether T" first="Thomas" last="Klockgether">Thomas Klockgether</name><affiliation><mods:affiliation>Department of Neurology, University of Bonn, Germany</mods:affiliation></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><mods:affiliation>Department of Neurology, Medical University of Innsbruck, Austria</mods:affiliation></affiliation><affiliation><mods:affiliation>European MSA Study Group, Innsbruck Medical University, Austria</mods:affiliation></affiliation></author><author><name sortKey="Wenning, Gregor" sort="Wenning, Gregor" uniqKey="Wenning G" first="Gregor" last="Wenning">Gregor Wenning</name><affiliation><mods:affiliation>Department of Neurology, Medical University of Innsbruck, Austria</mods:affiliation></affiliation><affiliation><mods:affiliation>European MSA Study Group, Innsbruck Medical University, Austria</mods:affiliation></affiliation></author><author><name sortKey="Schade Rittinger, Carmen" sort="Schade Rittinger, Carmen" uniqKey="Schade Rittinger C" first="Carmen" last="Schade-Brittinger">Carmen Schade-Brittinger</name><affiliation><mods:affiliation>Coordinating Center for Clinical Trials, Philipps‐University of Marburg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Oertel, Wolfgang H" sort="Oertel, Wolfgang H" uniqKey="Oertel W" first="Wolfgang H." last="Oertel">Wolfgang H. Oertel</name><affiliation><mods:affiliation>Department of Neurology, Philipps‐University of Marburg, Germany</mods:affiliation></affiliation><affiliation><mods:affiliation>Competence Network Parkinson‐Syndrome, Philipps‐University of Marburg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Eggert, Karla" sort="Eggert, Karla" uniqKey="Eggert K" first="Karla" last="Eggert">Karla Eggert</name><affiliation><mods:affiliation>Department of Neurology, Philipps‐University of Marburg, Germany</mods:affiliation></affiliation><affiliation><mods:affiliation>Competence Network Parkinson‐Syndrome, Philipps‐University of Marburg, Germany</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:7E3C331E554F887479122609783881EAE1EEE31D</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/mds.22732</idno><idno type="url">https://api.istex.fr/document/7E3C331E554F887479122609783881EAE1EEE31D/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000E63</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Minocycline 1‐year therapy in multiple‐system‐atrophy: Effect on clinical symptoms and [11C] (R)‐PK11195 PET (MEMSA‐trial)</title><author><name sortKey="Dodel, Richard" sort="Dodel, Richard" uniqKey="Dodel R" first="Richard" last="Dodel">Richard Dodel</name><affiliation><mods:affiliation>Department of Neurology, Philipps‐University of Marburg, Germany</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, University of Bonn, Germany</mods:affiliation></affiliation></author><author><name sortKey="Spottke, Annika" sort="Spottke, Annika" uniqKey="Spottke A" first="Annika" last="Spottke">Annika Spottke</name><affiliation><mods:affiliation>Department of Neurology, University of Bonn, Germany</mods:affiliation></affiliation></author><author><name sortKey="Gerhard, Alexander" sort="Gerhard, Alexander" uniqKey="Gerhard A" first="Alexander" last="Gerhard">Alexander Gerhard</name><affiliation><mods:affiliation>Wolfson Molecular Imaging Centre, The University of Manchester, United Kingdom</mods:affiliation></affiliation><affiliation><mods:affiliation>IMRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College; London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Reuss, Alexander" sort="Reuss, Alexander" uniqKey="Reuss A" first="Alexander" last="Reuss">Alexander Reuss</name><affiliation><mods:affiliation>Coordinating Center for Clinical Trials, Philipps‐University of Marburg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Reinecker, Sylvia" sort="Reinecker, Sylvia" uniqKey="Reinecker S" first="Sylvia" last="Reinecker">Sylvia Reinecker</name><affiliation><mods:affiliation>Coordinating Center for Clinical Trials, Philipps‐University of Marburg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Schimke, Nicole" sort="Schimke, Nicole" uniqKey="Schimke N" first="Nicole" last="Schimke">Nicole Schimke</name><affiliation><mods:affiliation>Department of Neurology, Philipps‐University of Marburg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Trenkwalder, Claudia" sort="Trenkwalder, Claudia" uniqKey="Trenkwalder C" first="Claudia" last="Trenkwalder">Claudia Trenkwalder</name><affiliation><mods:affiliation>Paracelsus‐Elena‐Clinic Kassel, Germany</mods:affiliation></affiliation></author><author><name sortKey="Sixel Ring, Friederike" sort="Sixel Ring, Friederike" uniqKey="Sixel Ring F" first="Friederike" last="Sixel-Döring">Friederike Sixel-Döring</name><affiliation><mods:affiliation>Paracelsus‐Elena‐Clinic Kassel, Germany</mods:affiliation></affiliation></author><author><name sortKey="Herting, Birgit" sort="Herting, Birgit" uniqKey="Herting B" first="Birgit" last="Herting">Birgit Herting</name><affiliation><mods:affiliation>Department of Neurology, Dresden University of Technology, Germany</mods:affiliation></affiliation></author><author><name sortKey="Kamm, Christoph" sort="Kamm, Christoph" uniqKey="Kamm C" first="Christoph" last="Kamm">Christoph Kamm</name><affiliation><mods:affiliation>Hertie‐Institute, University of Tübingen, Germany</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, University of Rostock, Germany</mods:affiliation></affiliation></author><author><name sortKey="Gasser, Thomas" sort="Gasser, Thomas" uniqKey="Gasser T" first="Thomas" last="Gasser">Thomas Gasser</name><affiliation><mods:affiliation>Hertie‐Institute, University of Tübingen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Sawires, Martin" sort="Sawires, Martin" uniqKey="Sawires M" first="Martin" last="Sawires">Martin Sawires</name><affiliation><mods:affiliation>Department of Neurology, Medical University of Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="Geser, Felix" sort="Geser, Felix" uniqKey="Geser F" first="Felix" last="Geser">Felix Geser</name><affiliation><mods:affiliation>Department of Neurology, Medical University of Innsbruck, Austria</mods:affiliation></affiliation><affiliation><mods:affiliation>European MSA Study Group, Innsbruck Medical University, Austria</mods:affiliation></affiliation></author><author><name sortKey="Kollensperger, Martin" sort="Kollensperger, Martin" uniqKey="Kollensperger M" first="Martin" last="Köllensperger">Martin Köllensperger</name><affiliation><mods:affiliation>Department of Neurology, Medical University of Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="Seppi, Klaus" sort="Seppi, Klaus" uniqKey="Seppi K" first="Klaus" last="Seppi">Klaus Seppi</name><affiliation><mods:affiliation>Department of Neurology, Medical University of Innsbruck, Austria</mods:affiliation></affiliation><affiliation><mods:affiliation>European MSA Study Group, Innsbruck Medical University, Austria</mods:affiliation></affiliation></author><author><name sortKey="Kloss, Manja" sort="Kloss, Manja" uniqKey="Kloss M" first="Manja" last="Kloss">Manja Kloss</name><affiliation><mods:affiliation>Department of Neurology, University of Heidelberg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Krause, Martin" sort="Krause, Martin" uniqKey="Krause M" first="Martin" last="Krause">Martin Krause</name><affiliation><mods:affiliation>Department of Neurology, University of Heidelberg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Daniels, Christine" sort="Daniels, Christine" uniqKey="Daniels C" first="Christine" last="Daniels">Christine Daniels</name><affiliation><mods:affiliation>Department of Neurology, University of Kiel, Germany</mods:affiliation></affiliation></author><author><name sortKey="Deuschl, Gunther" sort="Deuschl, Gunther" uniqKey="Deuschl G" first="Günther" last="Deuschl">Günther Deuschl</name><affiliation><mods:affiliation>Department of Neurology, University of Kiel, Germany</mods:affiliation></affiliation></author><author><name sortKey="Bottger, Silke" sort="Bottger, Silke" uniqKey="Bottger S" first="Silke" last="Böttger">Silke Böttger</name><affiliation><mods:affiliation>Department of Neurology, University of Würzburg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Naumann, Markus" sort="Naumann, Markus" uniqKey="Naumann M" first="Markus" last="Naumann">Markus Naumann</name><affiliation><mods:affiliation>Department of Neurology, University of Würzburg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Lipp, Axel" sort="Lipp, Axel" uniqKey="Lipp A" first="Axel" last="Lipp">Axel Lipp</name><affiliation><mods:affiliation>Wolfson Molecular Imaging Centre, The University of Manchester, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Gruber, Doreen" sort="Gruber, Doreen" uniqKey="Gruber D" first="Doreen" last="Gruber">Doreen Gruber</name><affiliation><mods:affiliation>Department of Neurology, University of Berlin, Germany</mods:affiliation></affiliation></author><author><name sortKey="Kupsch, Andreas" sort="Kupsch, Andreas" uniqKey="Kupsch A" first="Andreas" last="Kupsch">Andreas Kupsch</name><affiliation><mods:affiliation>Department of Neurology, University of Berlin, Germany</mods:affiliation></affiliation></author><author><name sortKey="Du, Yansheng" sort="Du, Yansheng" uniqKey="Du Y" first="Yansheng" last="Du">Yansheng Du</name><affiliation><mods:affiliation>Department of Neurology, Indiana University Medical School, Indianapolis, Indiana, USA</mods:affiliation></affiliation></author><author><name sortKey="Turkheimer, Federico" sort="Turkheimer, Federico" uniqKey="Turkheimer F" first="Federico" last="Turkheimer">Federico Turkheimer</name><affiliation><mods:affiliation>IMRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College; London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Brooks, David J" sort="Brooks, David J" uniqKey="Brooks D" first="David J." last="Brooks">David J. Brooks</name><affiliation><mods:affiliation>IMRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College; London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Klockgether, Thomas" sort="Klockgether, Thomas" uniqKey="Klockgether T" first="Thomas" last="Klockgether">Thomas Klockgether</name><affiliation><mods:affiliation>Department of Neurology, University of Bonn, Germany</mods:affiliation></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><mods:affiliation>Department of Neurology, Medical University of Innsbruck, Austria</mods:affiliation></affiliation><affiliation><mods:affiliation>European MSA Study Group, Innsbruck Medical University, Austria</mods:affiliation></affiliation></author><author><name sortKey="Wenning, Gregor" sort="Wenning, Gregor" uniqKey="Wenning G" first="Gregor" last="Wenning">Gregor Wenning</name><affiliation><mods:affiliation>Department of Neurology, Medical University of Innsbruck, Austria</mods:affiliation></affiliation><affiliation><mods:affiliation>European MSA Study Group, Innsbruck Medical University, Austria</mods:affiliation></affiliation></author><author><name sortKey="Schade Rittinger, Carmen" sort="Schade Rittinger, Carmen" uniqKey="Schade Rittinger C" first="Carmen" last="Schade-Brittinger">Carmen Schade-Brittinger</name><affiliation><mods:affiliation>Coordinating Center for Clinical Trials, Philipps‐University of Marburg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Oertel, Wolfgang H" sort="Oertel, Wolfgang H" uniqKey="Oertel W" first="Wolfgang H." last="Oertel">Wolfgang H. Oertel</name><affiliation><mods:affiliation>Department of Neurology, Philipps‐University of Marburg, Germany</mods:affiliation></affiliation><affiliation><mods:affiliation>Competence Network Parkinson‐Syndrome, Philipps‐University of Marburg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Eggert, Karla" sort="Eggert, Karla" uniqKey="Eggert K" first="Karla" last="Eggert">Karla Eggert</name><affiliation><mods:affiliation>Department of Neurology, Philipps‐University of Marburg, Germany</mods:affiliation></affiliation><affiliation><mods:affiliation>Competence Network Parkinson‐Syndrome, Philipps‐University of Marburg, Germany</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-01-15">2010-01-15</date><biblScope unit="volume">25</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="97">97</biblScope><biblScope unit="page" to="107">107</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">7E3C331E554F887479122609783881EAE1EEE31D</idno><idno type="DOI">10.1002/mds.22732</idno><idno type="ArticleID">MDS22732</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>PET</term><term>minocycline</term><term>multiple system atrophy</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The aim of the study was to investigate the efficacy of the antibiotic minocycline as a drug treatment in patients with Multiple‐System‐Atrophy Parkinson‐type (MSA‐P). Sixty‐three patients were randomized to minocycline 200 mg/d (n = 32) or a matching placebo (n = 31). The primary outcome variable was the change in the value of the motor score of the Unified Multiple‐System‐Atrophy Rating‐Scale (UMSARSII) from baseline to 48 weeks. Secondary outcome variables included subscores and individual Parkinsonian symptoms as determined by the UMSARS and the Unified‐Parkinson's‐Disease Rating‐Scale (UPDRS). Health‐related quality of life (HrQoL) was assessed using the EQ‐5D and SF‐12. “Progression rate” was assumed to be reflected in the change in motor function over 48 weeks. At 24 weeks and 48 weeks of follow‐up, there was a significant deterioration in motor scores in both groups, but neither the change in UMSARSII nor in UPDRSIII differed significantly between treatment groups, i.e. “progression rate” was considered to be similar in both treatment arms. HrQoL did not differ among the two treatment arms. In a small subgroup of patients (n = 8; minocycline = 3, placebo = 5)[11C](R)‐PK11195‐PET was performed. The three patients in the minocycline group had an attenuated mean increase in microglial activation as compared to the placebo group (P = 0.07) and in two of them individually showed decreased [11C](R)‐PK11195 binding actually decreased. These preliminary PET‐data suggest that minocycline may interfere with microglial activation. The relevance of this observation requires further investigation. This prospective, 48 week, randomized, double‐blind, multinational study failed to show a clinical effect of minocycline on symptom severity as assessed by clinical motor function. © 2009 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Richard Dodel MD</name><affiliations><json:string>Department of Neurology, Philipps‐University of Marburg, Germany</json:string><json:string>Department of Neurology, University of Bonn, Germany</json:string></affiliations></json:item><json:item><name>Annika Spottke MD</name><affiliations><json:string>Department of Neurology, University of Bonn, Germany</json:string></affiliations></json:item><json:item><name>Alexander Gerhard MD</name><affiliations><json:string>Wolfson Molecular Imaging Centre, The University of Manchester, United Kingdom</json:string><json:string>IMRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College; London, United Kingdom</json:string></affiliations></json:item><json:item><name>Alexander Reuss MSc</name><affiliations><json:string>Coordinating Center for Clinical Trials, Philipps‐University of Marburg, Germany</json:string></affiliations></json:item><json:item><name>Sylvia Reinecker MSc</name><affiliations><json:string>Coordinating Center for Clinical Trials, Philipps‐University of Marburg, Germany</json:string></affiliations></json:item><json:item><name>Nicole Schimke MD</name><affiliations><json:string>Department of Neurology, Philipps‐University of Marburg, Germany</json:string></affiliations></json:item><json:item><name>Claudia Trenkwalder MD</name><affiliations><json:string>Paracelsus‐Elena‐Clinic Kassel, Germany</json:string></affiliations></json:item><json:item><name>Friederike Sixel‐Döring MD</name><affiliations><json:string>Paracelsus‐Elena‐Clinic Kassel, Germany</json:string></affiliations></json:item><json:item><name>Birgit Herting MD</name><affiliations><json:string>Department of Neurology, Dresden University of Technology, Germany</json:string></affiliations></json:item><json:item><name>Christoph Kamm MD</name><affiliations><json:string>Hertie‐Institute, University of Tübingen, Germany</json:string><json:string>Department of Neurology, University of Rostock, Germany</json:string></affiliations></json:item><json:item><name>Thomas Gasser MD</name><affiliations><json:string>Hertie‐Institute, University of Tübingen, Germany</json:string></affiliations></json:item><json:item><name>Martin Sawires MD</name><affiliations><json:string>Department of Neurology, Medical University of Innsbruck, Austria</json:string></affiliations></json:item><json:item><name>Felix Geser MD, PhD</name><affiliations><json:string>Department of Neurology, Medical University of Innsbruck, Austria</json:string><json:string>European MSA Study Group, Innsbruck Medical University, Austria</json:string></affiliations></json:item><json:item><name>Martin Köllensperger MD</name><affiliations><json:string>Department of Neurology, Medical University of Innsbruck, Austria</json:string></affiliations></json:item><json:item><name>Klaus Seppi MD</name><affiliations><json:string>Department of Neurology, Medical University of Innsbruck, Austria</json:string><json:string>European MSA Study Group, Innsbruck Medical University, Austria</json:string></affiliations></json:item><json:item><name>Manja Kloss MD</name><affiliations><json:string>Department of Neurology, University of Heidelberg, Germany</json:string></affiliations></json:item><json:item><name>Martin Krause MD</name><affiliations><json:string>Department of Neurology, University of Heidelberg, Germany</json:string></affiliations></json:item><json:item><name>Christine Daniels MD</name><affiliations><json:string>Department of Neurology, University of Kiel, Germany</json:string></affiliations></json:item><json:item><name>Günther Deuschl MD</name><affiliations><json:string>Department of Neurology, University of Kiel, Germany</json:string></affiliations></json:item><json:item><name>Silke Böttger MD</name><affiliations><json:string>Department of Neurology, University of Würzburg, Germany</json:string></affiliations></json:item><json:item><name>Markus Naumann MD</name><affiliations><json:string>Department of Neurology, University of Würzburg, Germany</json:string></affiliations></json:item><json:item><name>Axel Lipp MD</name><affiliations><json:string>Wolfson Molecular Imaging Centre, The University of Manchester, United Kingdom</json:string></affiliations></json:item><json:item><name>Doreen Gruber MD</name><affiliations><json:string>Department of Neurology, University of Berlin, Germany</json:string></affiliations></json:item><json:item><name>Andreas Kupsch MD, PhD</name><affiliations><json:string>Department of Neurology, University of Berlin, Germany</json:string></affiliations></json:item><json:item><name>Yansheng Du PhD</name><affiliations><json:string>Department of Neurology, Indiana University Medical School, Indianapolis, Indiana, USA</json:string></affiliations></json:item><json:item><name>Federico Turkheimer PhD</name><affiliations><json:string>IMRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College; London, United Kingdom</json:string></affiliations></json:item><json:item><name>David J. Brooks MD</name><affiliations><json:string>IMRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College; London, United Kingdom</json:string></affiliations></json:item><json:item><name>Thomas Klockgether MD</name><affiliations><json:string>Department of Neurology, University of Bonn, Germany</json:string></affiliations></json:item><json:item><name>Werner Poewe MD</name><affiliations><json:string>Department of Neurology, Medical University of Innsbruck, Austria</json:string><json:string>European MSA Study Group, Innsbruck Medical University, Austria</json:string></affiliations></json:item><json:item><name>Gregor Wenning MD, PhD</name><affiliations><json:string>Department of Neurology, Medical University of Innsbruck, Austria</json:string><json:string>European MSA Study Group, Innsbruck Medical University, Austria</json:string></affiliations></json:item><json:item><name>Carmen Schade‐Brittinger , MSc</name><affiliations><json:string>Coordinating Center for Clinical Trials, Philipps‐University of Marburg, Germany</json:string></affiliations></json:item><json:item><name>Wolfgang H. Oertel MD</name><affiliations><json:string>Department of Neurology, Philipps‐University of Marburg, Germany</json:string><json:string>Competence Network Parkinson‐Syndrome, Philipps‐University of Marburg, Germany</json:string></affiliations></json:item><json:item><name>Karla Eggert MD</name><affiliations><json:string>Department of Neurology, Philipps‐University of Marburg, Germany</json:string><json:string>Competence Network Parkinson‐Syndrome, Philipps‐University of Marburg, Germany</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>multiple system atrophy</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>minocycline</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>PET</value></json:item></subject><articleId><json:string>MDS22732</json:string></articleId><language><json:string>eng</json:string></language><abstract>The aim of the study was to investigate the efficacy of the antibiotic minocycline as a drug treatment in patients with Multiple‐System‐Atrophy Parkinson‐type (MSA‐P). Sixty‐three patients were randomized to minocycline 200 mg/d (n = 32) or a matching placebo (n = 31). The primary outcome variable was the change in the value of the motor score of the Unified Multiple‐System‐Atrophy Rating‐Scale (UMSARSII) from baseline to 48 weeks. Secondary outcome variables included subscores and individual Parkinsonian symptoms as determined by the UMSARS and the Unified‐Parkinson's‐Disease Rating‐Scale (UPDRS). Health‐related quality of life (HrQoL) was assessed using the EQ‐5D and SF‐12. “Progression rate” was assumed to be reflected in the change in motor function over 48 weeks. At 24 weeks and 48 weeks of follow‐up, there was a significant deterioration in motor scores in both groups, but neither the change in UMSARSII nor in UPDRSIII differed significantly between treatment groups, i.e. “progression rate” was considered to be similar in both treatment arms. HrQoL did not differ among the two treatment arms. In a small subgroup of patients (n = 8; minocycline = 3, placebo = 5)[11C](R)‐PK11195‐PET was performed. The three patients in the minocycline group had an attenuated mean increase in microglial activation as compared to the placebo group (P = 0.07) and in two of them individually showed decreased [11C](R)‐PK11195 binding actually decreased. These preliminary PET‐data suggest that minocycline may interfere with microglial activation. The relevance of this observation requires further investigation. This prospective, 48 week, randomized, double‐blind, multinational study failed to show a clinical effect of minocycline on symptom severity as assessed by clinical motor function. © 2009 Movement Disorder Society</abstract><qualityIndicators><score>8</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>3</keywordCount><abstractCharCount>1833</abstractCharCount><pdfWordCount>5786</pdfWordCount><pdfCharCount>39595</pdfCharCount><pdfPageCount>11</pdfPageCount><abstractWordCount>270</abstractWordCount></qualityIndicators><title>Minocycline 1‐year therapy in multiple‐system‐atrophy: Effect on clinical symptoms and [11C] (R)‐PK11195 PET (MEMSA‐trial)</title><genre><json:string>article</json:string></genre><host><volume>25</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>11</total><last>107</last><first>97</first></pages><issn><json:string>0885-3185</json:string></issn><issue>1</issue><subject><json:item><value>Research Article</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2010</publicationDate><copyrightDate>2010</copyrightDate><doi><json:string>10.1002/mds.22732</json:string></doi><id>7E3C331E554F887479122609783881EAE1EEE31D</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/7E3C331E554F887479122609783881EAE1EEE31D/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/7E3C331E554F887479122609783881EAE1EEE31D/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/7E3C331E554F887479122609783881EAE1EEE31D/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Minocycline 1‐year therapy in multiple‐system‐atrophy: Effect on clinical symptoms and [11C] (R)‐PK11195 PET (MEMSA‐trial)</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2010</date></publicationStmt><notesStmt><note type="content">*Potential conflict of interest: The authors report no conflicts of interest and have no financial disclosures to make in respect to this article.</note><note>German Ministry of Education and Research - No. BMBF Nr. 01GI9901; No. 01GI0201; No. 01GI040;</note><note>European MSA Study Group</note><note>Willy Robert Pitzer foundation - No. 16/03; No. PDS UK MAP; No. 02/04;</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Minocycline 1‐year therapy in multiple‐system‐atrophy: Effect on clinical symptoms and [11C] (R)‐PK11195 PET (MEMSA‐trial)</title><author><persName><forename type="first">Richard</forename><surname>Dodel</surname></persName><roleName type="degree">MD</roleName><note type="biography">Richard Dodel, Annika Spottke, Alexander Gerhard, Alexander Reuss, Wolfgang H. Oertel, and Karla Eggert contributed equally to this work.</note><affiliation>Richard Dodel, Annika Spottke, Alexander Gerhard, Alexander Reuss, Wolfgang H. Oertel, and Karla Eggert contributed equally to this work.</affiliation><note type="correspondence"><p>Correspondence: Department of Neurology, Philipps‐University Marburg, Rudolf‐Bultmannstr. 8, 35039 Marburg, Germany</p></note><affiliation>Department of Neurology, Philipps‐University of Marburg, Germany</affiliation><affiliation>Department of Neurology, University of Bonn, Germany</affiliation></author><author><persName><forename type="first">Annika</forename><surname>Spottke</surname></persName><roleName type="degree">MD</roleName><note type="biography">Richard Dodel, Annika Spottke, Alexander Gerhard, Alexander Reuss, Wolfgang H. Oertel, and Karla Eggert contributed equally to this work.</note><affiliation>Richard Dodel, Annika Spottke, Alexander Gerhard, Alexander Reuss, Wolfgang H. Oertel, and Karla Eggert contributed equally to this work.</affiliation><affiliation>Department of Neurology, University of Bonn, Germany</affiliation></author><author><persName><forename type="first">Alexander</forename><surname>Gerhard</surname></persName><roleName type="degree">MD</roleName><note type="biography">Richard Dodel, Annika Spottke, Alexander Gerhard, Alexander Reuss, Wolfgang H. Oertel, and Karla Eggert contributed equally to this work.</note><affiliation>Richard Dodel, Annika Spottke, Alexander Gerhard, Alexander Reuss, Wolfgang H. Oertel, and Karla Eggert contributed equally to this work.</affiliation><affiliation>Wolfson Molecular Imaging Centre, The University of Manchester, United Kingdom</affiliation><affiliation>IMRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College; London, United Kingdom</affiliation></author><author><persName><forename type="first">Alexander</forename><surname>Reuss</surname></persName><roleName type="degree">MSc</roleName><note type="biography">Richard Dodel, Annika Spottke, Alexander Gerhard, Alexander Reuss, Wolfgang H. Oertel, and Karla Eggert contributed equally to this work.</note><affiliation>Richard Dodel, Annika Spottke, Alexander Gerhard, Alexander Reuss, Wolfgang H. Oertel, and Karla Eggert contributed equally to this work.</affiliation><affiliation>Coordinating Center for Clinical Trials, Philipps‐University of Marburg, Germany</affiliation></author><author><persName><forename type="first">Sylvia</forename><surname>Reinecker</surname></persName><roleName type="degree">MSc</roleName><affiliation>Coordinating Center for Clinical Trials, Philipps‐University of Marburg, Germany</affiliation></author><author><persName><forename type="first">Nicole</forename><surname>Schimke</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, Philipps‐University of Marburg, Germany</affiliation></author><author><persName><forename type="first">Claudia</forename><surname>Trenkwalder</surname></persName><roleName type="degree">MD</roleName><affiliation>Paracelsus‐Elena‐Clinic Kassel, Germany</affiliation></author><author><persName><forename type="first">Friederike</forename><surname>Sixel‐Döring</surname></persName><roleName type="degree">MD</roleName><affiliation>Paracelsus‐Elena‐Clinic Kassel, Germany</affiliation></author><author><persName><forename type="first">Birgit</forename><surname>Herting</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, Dresden University of Technology, Germany</affiliation></author><author><persName><forename type="first">Christoph</forename><surname>Kamm</surname></persName><roleName type="degree">MD</roleName><affiliation>Hertie‐Institute, University of Tübingen, Germany</affiliation><affiliation>Department of Neurology, University of Rostock, Germany</affiliation></author><author><persName><forename type="first">Thomas</forename><surname>Gasser</surname></persName><roleName type="degree">MD</roleName><affiliation>Hertie‐Institute, University of Tübingen, Germany</affiliation></author><author><persName><forename type="first">Martin</forename><surname>Sawires</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, Medical University of Innsbruck, Austria</affiliation></author><author><persName><forename type="first">Felix</forename><surname>Geser</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Department of Neurology, Medical University of Innsbruck, Austria</affiliation><affiliation>European MSA Study Group, Innsbruck Medical University, Austria</affiliation></author><author><persName><forename type="first">Martin</forename><surname>Köllensperger</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, Medical University of Innsbruck, Austria</affiliation></author><author><persName><forename type="first">Klaus</forename><surname>Seppi</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, Medical University of Innsbruck, Austria</affiliation><affiliation>European MSA Study Group, Innsbruck Medical University, Austria</affiliation></author><author><persName><forename type="first">Manja</forename><surname>Kloss</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, University of Heidelberg, Germany</affiliation></author><author><persName><forename type="first">Martin</forename><surname>Krause</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, University of Heidelberg, Germany</affiliation></author><author><persName><forename type="first">Christine</forename><surname>Daniels</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, University of Kiel, Germany</affiliation></author><author><persName><forename type="first">Günther</forename><surname>Deuschl</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, University of Kiel, Germany</affiliation></author><author><persName><forename type="first">Silke</forename><surname>Böttger</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, University of Würzburg, Germany</affiliation></author><author><persName><forename type="first">Markus</forename><surname>Naumann</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, University of Würzburg, Germany</affiliation></author><author><persName><forename type="first">Axel</forename><surname>Lipp</surname></persName><roleName type="degree">MD</roleName><affiliation>Wolfson Molecular Imaging Centre, The University of Manchester, United Kingdom</affiliation></author><author><persName><forename type="first">Doreen</forename><surname>Gruber</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, University of Berlin, Germany</affiliation></author><author><persName><forename type="first">Andreas</forename><surname>Kupsch</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Department of Neurology, University of Berlin, Germany</affiliation></author><author><persName><forename type="first">Yansheng</forename><surname>Du</surname></persName><roleName type="degree">PhD</roleName><affiliation>Department of Neurology, Indiana University Medical School, Indianapolis, Indiana, USA</affiliation></author><author><persName><forename type="first">Federico</forename><surname>Turkheimer</surname></persName><roleName type="degree">PhD</roleName><affiliation>IMRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College; London, United Kingdom</affiliation></author><author><persName><forename type="first">David J.</forename><surname>Brooks</surname></persName><roleName type="degree">MD</roleName><affiliation>IMRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College; London, United Kingdom</affiliation></author><author><persName><forename type="first">Thomas</forename><surname>Klockgether</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, University of Bonn, Germany</affiliation></author><author><persName><forename type="first">Werner</forename><surname>Poewe</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, Medical University of Innsbruck, Austria</affiliation><affiliation>European MSA Study Group, Innsbruck Medical University, Austria</affiliation></author><author><persName><forename type="first">Gregor</forename><surname>Wenning</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Department of Neurology, Medical University of Innsbruck, Austria</affiliation><affiliation>European MSA Study Group, Innsbruck Medical University, Austria</affiliation></author><author><persName><forename type="first">Carmen</forename><surname>Schade‐Brittinger</surname></persName><roleName type="degree">, MSc</roleName><affiliation>Coordinating Center for Clinical Trials, Philipps‐University of Marburg, Germany</affiliation></author><author><persName><forename type="first">Wolfgang H.</forename><surname>Oertel</surname></persName><roleName type="degree">MD</roleName><note type="biography">Richard Dodel, Annika Spottke, Alexander Gerhard, Alexander Reuss, Wolfgang H. Oertel, and Karla Eggert contributed equally to this work.</note><affiliation>Richard Dodel, Annika Spottke, Alexander Gerhard, Alexander Reuss, Wolfgang H. Oertel, and Karla Eggert contributed equally to this work.</affiliation><affiliation>Department of Neurology, Philipps‐University of Marburg, Germany</affiliation><affiliation>Competence Network Parkinson‐Syndrome, Philipps‐University of Marburg, Germany</affiliation></author><author><persName><forename type="first">Karla</forename><surname>Eggert</surname></persName><roleName type="degree">MD</roleName><note type="biography">Richard Dodel, Annika Spottke, Alexander Gerhard, Alexander Reuss, Wolfgang H. Oertel, and Karla Eggert contributed equally to this work.</note><affiliation>Richard Dodel, Annika Spottke, Alexander Gerhard, Alexander Reuss, Wolfgang H. Oertel, and Karla Eggert contributed equally to this work.</affiliation><affiliation>Department of Neurology, Philipps‐University of Marburg, Germany</affiliation><affiliation>Competence Network Parkinson‐Syndrome, Philipps‐University of Marburg, Germany</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-01-15"></date><biblScope unit="volume">25</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="97">97</biblScope><biblScope unit="page" to="107">107</biblScope></imprint></monogr><idno type="istex">7E3C331E554F887479122609783881EAE1EEE31D</idno><idno type="DOI">10.1002/mds.22732</idno><idno type="ArticleID">MDS22732</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2010</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>The aim of the study was to investigate the efficacy of the antibiotic minocycline as a drug treatment in patients with Multiple‐System‐Atrophy Parkinson‐type (MSA‐P). Sixty‐three patients were randomized to minocycline 200 mg/d (n = 32) or a matching placebo (n = 31). The primary outcome variable was the change in the value of the motor score of the Unified Multiple‐System‐Atrophy Rating‐Scale (UMSARSII) from baseline to 48 weeks. Secondary outcome variables included subscores and individual Parkinsonian symptoms as determined by the UMSARS and the Unified‐Parkinson's‐Disease Rating‐Scale (UPDRS). Health‐related quality of life (HrQoL) was assessed using the EQ‐5D and SF‐12. “Progression rate” was assumed to be reflected in the change in motor function over 48 weeks. At 24 weeks and 48 weeks of follow‐up, there was a significant deterioration in motor scores in both groups, but neither the change in UMSARSII nor in UPDRSIII differed significantly between treatment groups, i.e. “progression rate” was considered to be similar in both treatment arms. HrQoL did not differ among the two treatment arms. In a small subgroup of patients (n = 8; minocycline = 3, placebo = 5)[11C](R)‐PK11195‐PET was performed. The three patients in the minocycline group had an attenuated mean increase in microglial activation as compared to the placebo group (P = 0.07) and in two of them individually showed decreased [11C](R)‐PK11195 binding actually decreased. These preliminary PET‐data suggest that minocycline may interfere with microglial activation. The relevance of this observation requires further investigation. This prospective, 48 week, randomized, double‐blind, multinational study failed to show a clinical effect of minocycline on symptom severity as assessed by clinical motor function. © 2009 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>multiple system atrophy</term></item><item><term>minocycline</term></item><item><term>PET</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2008-01-23">Received</change><change when="2009-07-08">Registration</change><change when="2010-01-15">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/7E3C331E554F887479122609783881EAE1EEE31D/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="10"><doi origin="wiley" registered="yes">10.1002/mds.v25:1</doi><numberingGroup><numbering type="journalVolume" number="25">25</numbering><numbering type="journalIssue">1</numbering></numberingGroup><coverDate startDate="2010-01-15">15 January 2010</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="14" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.22732</doi><idGroup><id type="unit" value="MDS22732"></id></idGroup><countGroup><count type="pageTotal" number="11"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2009 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2008-01-23"></event><event type="manuscriptRevised" date="2009-04-29"></event><event type="manuscriptAccepted" date="2009-07-08"></event><event type="firstOnline" date="2009-12-11"></event><event type="publishedOnlineFinalForm" date="2010-01-25"></event><event type="publishedOnlineAcceptedOrEarlyUnpaginated" date="2009-12-11"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:3.1.9 mode:FullText" date="2013-01-28"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">97</numbering><numbering type="pageLast">107</numbering></numberingGroup><correspondenceTo>Department of Neurology, Philipps‐University Marburg, Rudolf‐Bultmannstr. 8, 35039 Marburg, Germany</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS22732.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="2"></count><count type="tableTotal" number="3"></count><count type="referenceTotal" number="44"></count><count type="wordTotal" number="8348"></count></countGroup><titleGroup><title type="main" xml:lang="en">Minocycline 1‐year therapy in multiple‐system‐atrophy: Effect on clinical symptoms and [<sup>11</sup>C] <i>(R)</i>‐PK11195 PET (MEMSA‐trial)<link href="#fn5"></link></title><title type="short" xml:lang="en"><fi>Efficacy of Minocycline for Patients with MSA‐P</fi></title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1 #af2" corresponding="yes" noteRef="#fn6"><personName><givenNames>Richard</givenNames><familyName>Dodel</familyName><degrees>MD</degrees></personName><contactDetails><email normalForm="richard.dodel@med.uni-marburg.de">richard.dodel@med.uni‐marburg.de</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2" noteRef="#fn6"><personName><givenNames>Annika</givenNames><familyName>Spottke</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af3 #af16" noteRef="#fn6"><personName><givenNames>Alexander</givenNames><familyName>Gerhard</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af4" noteRef="#fn6"><personName><givenNames>Alexander</givenNames><familyName>Reuss</familyName><degrees>MSc</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Sylvia</givenNames><familyName>Reinecker</familyName><degrees>MSc</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Nicole</givenNames><familyName>Schimke</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af6"><personName><givenNames>Claudia</givenNames><familyName>Trenkwalder</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af6"><personName><givenNames>Friederike</givenNames><familyName>Sixel‐Döring</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au9" creatorRole="author" affiliationRef="#af7"><personName><givenNames>Birgit</givenNames><familyName>Herting</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au10" creatorRole="author" affiliationRef="#af8 #af9"><personName><givenNames>Christoph</givenNames><familyName>Kamm</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au11" creatorRole="author" affiliationRef="#af8"><personName><givenNames>Thomas</givenNames><familyName>Gasser</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au12" creatorRole="author" affiliationRef="#af10"><personName><givenNames>Martin</givenNames><familyName>Sawires</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au13" creatorRole="author" affiliationRef="#af10 #af11"><personName><givenNames>Felix</givenNames><familyName>Geser</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au14" creatorRole="author" affiliationRef="#af10"><personName><givenNames>Martin</givenNames><familyName>Köllensperger</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au15" creatorRole="author" affiliationRef="#af10 #af11"><personName><givenNames>Klaus</givenNames><familyName>Seppi</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au16" creatorRole="author" affiliationRef="#af12"><personName><givenNames>Manja</givenNames><familyName>Kloss</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au17" creatorRole="author" affiliationRef="#af12"><personName><givenNames>Martin</givenNames><familyName>Krause</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au18" creatorRole="author" affiliationRef="#af13"><personName><givenNames>Christine</givenNames><familyName>Daniels</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au19" creatorRole="author" affiliationRef="#af13"><personName><givenNames>Günther</givenNames><familyName>Deuschl</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au20" creatorRole="author" affiliationRef="#af14"><personName><givenNames>Silke</givenNames><familyName>Böttger</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au21" creatorRole="author" affiliationRef="#af14"><personName><givenNames>Markus</givenNames><familyName>Naumann</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au22" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Axel</givenNames><familyName>Lipp</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au23" creatorRole="author" affiliationRef="#af15"><personName><givenNames>Doreen</givenNames><familyName>Gruber</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au24" creatorRole="author" affiliationRef="#af15"><personName><givenNames>Andreas</givenNames><familyName>Kupsch</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au25" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Yansheng</givenNames><familyName>Du</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au26" creatorRole="author" affiliationRef="#af16"><personName><givenNames>Federico</givenNames><familyName>Turkheimer</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au27" creatorRole="author" affiliationRef="#af16"><personName><givenNames>David J.</givenNames><familyName>Brooks</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au28" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Thomas</givenNames><familyName>Klockgether</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au29" creatorRole="author" affiliationRef="#af10 #af11"><personName><givenNames>Werner</givenNames><familyName>Poewe</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au30" creatorRole="author" affiliationRef="#af10 #af11"><personName><givenNames>Gregor</givenNames><familyName>Wenning</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au31" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Carmen</givenNames><familyName>Schade‐Brittinger</familyName><degrees>, MSc</degrees></personName></creator><creator xml:id="au32" creatorRole="author" affiliationRef="#af1 #af17" noteRef="#fn6"><personName><givenNames>Wolfgang H.</givenNames><familyName>Oertel</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au33" creatorRole="author" affiliationRef="#af1 #af17" noteRef="#fn6"><personName><givenNames>Karla</givenNames><familyName>Eggert</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="DE" type="organization"><unparsedAffiliation>Department of Neurology, Philipps‐University of Marburg, Germany</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="DE" type="organization"><unparsedAffiliation>Department of Neurology, University of Bonn, Germany</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="GB" type="organization"><unparsedAffiliation>Wolfson Molecular Imaging Centre, The University of Manchester, United Kingdom</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="DE" type="organization"><unparsedAffiliation>Coordinating Center for Clinical Trials, Philipps‐University of Marburg, Germany</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, Indiana University Medical School, Indianapolis, Indiana, USA</unparsedAffiliation></affiliation><affiliation xml:id="af6" countryCode="DE" type="organization"><unparsedAffiliation>Paracelsus‐Elena‐Clinic Kassel, Germany</unparsedAffiliation></affiliation><affiliation xml:id="af7" countryCode="DE" type="organization"><unparsedAffiliation>Department of Neurology, Dresden University of Technology, Germany</unparsedAffiliation></affiliation><affiliation xml:id="af8" countryCode="DE" type="organization"><unparsedAffiliation>Hertie‐Institute, University of Tübingen, Germany</unparsedAffiliation></affiliation><affiliation xml:id="af9" countryCode="DE" type="organization"><unparsedAffiliation>Department of Neurology, University of Rostock, Germany</unparsedAffiliation></affiliation><affiliation xml:id="af10" countryCode="AT" type="organization"><unparsedAffiliation>Department of Neurology, Medical University of Innsbruck, Austria</unparsedAffiliation></affiliation><affiliation xml:id="af11" countryCode="AT" type="organization"><unparsedAffiliation>European MSA Study Group, Innsbruck Medical University, Austria</unparsedAffiliation></affiliation><affiliation xml:id="af12" countryCode="DE" type="organization"><unparsedAffiliation>Department of Neurology, University of Heidelberg, Germany</unparsedAffiliation></affiliation><affiliation xml:id="af13" countryCode="DE" type="organization"><unparsedAffiliation>Department of Neurology, University of Kiel, Germany</unparsedAffiliation></affiliation><affiliation xml:id="af14" countryCode="DE" type="organization"><unparsedAffiliation>Department of Neurology, University of Würzburg, Germany</unparsedAffiliation></affiliation><affiliation xml:id="af15" countryCode="DE" type="organization"><unparsedAffiliation>Department of Neurology, University of Berlin, Germany</unparsedAffiliation></affiliation><affiliation xml:id="af16" countryCode="GB" type="organization"><unparsedAffiliation>IMRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College; London, United Kingdom</unparsedAffiliation></affiliation><affiliation xml:id="af17" countryCode="DE" type="organization"><unparsedAffiliation>Competence Network Parkinson‐Syndrome, Philipps‐University of Marburg, Germany</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">multiple system atrophy</keyword><keyword xml:id="kwd2">minocycline</keyword><keyword xml:id="kwd3">PET</keyword></keywordGroup><fundingInfo><fundingAgency>German Ministry of Education and Research</fundingAgency><fundingNumber>BMBF Nr. 01GI9901</fundingNumber><fundingNumber>01GI0201</fundingNumber><fundingNumber>01GI040</fundingNumber></fundingInfo><fundingInfo><fundingAgency>European MSA Study Group</fundingAgency></fundingInfo><fundingInfo><fundingAgency>Willy Robert Pitzer foundation</fundingAgency><fundingNumber>16/03</fundingNumber><fundingNumber>PDS UK MAP</fundingNumber><fundingNumber>02/04</fundingNumber></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>The aim of the study was to investigate the efficacy of the antibiotic minocycline as a drug treatment in patients with Multiple‐System‐Atrophy Parkinson‐type (MSA‐P). Sixty‐three patients were randomized to minocycline 200 mg/d (n = 32) or a matching placebo (n = 31). The primary outcome variable was the change in the value of the motor score of the Unified Multiple‐System‐Atrophy Rating‐Scale (UMSARSII) from baseline to 48 weeks. Secondary outcome variables included subscores and individual Parkinsonian symptoms as determined by the UMSARS and the Unified‐Parkinson's‐Disease Rating‐Scale (UPDRS). Health‐related quality of life (HrQoL) was assessed using the EQ‐5D and SF‐12. “Progression rate” was assumed to be reflected in the change in motor function over 48 weeks. At 24 weeks and 48 weeks of follow‐up, there was a significant deterioration in motor scores in both groups, but neither the change in UMSARSII nor in UPDRSIII differed significantly between treatment groups, i.e. “progression rate” was considered to be similar in both treatment arms. HrQoL did not differ among the two treatment arms. In a small subgroup of patients (n = 8; minocycline = 3, placebo = 5)[<sup>11</sup>C]<i>(R)</i>‐PK11195‐PET was performed. The three patients in the minocycline group had an attenuated mean increase in microglial activation as compared to the placebo group (P = 0.07) and in two of them individually showed decreased [11C]<i>(R)</i>‐PK11195 binding actually decreased. These preliminary PET‐data suggest that minocycline may interfere with microglial activation. The relevance of this observation requires further investigation. This prospective, 48 week, randomized, double‐blind, multinational study failed to show a clinical effect of minocycline on symptom severity as assessed by clinical motor function. © 2009 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn5"><p>Potential conflict of interest: The authors report no conflicts of interest and have no financial disclosures to make in respect to this article.</p></note><note xml:id="fn6"><p>Richard Dodel, Annika Spottke, Alexander Gerhard, Alexander Reuss, Wolfgang H. Oertel, and Karla Eggert contributed equally to this work.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Minocycline 1‐year therapy in multiple‐system‐atrophy: Effect on clinical symptoms and [11C] (R)‐PK11195 PET (MEMSA‐trial)</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Efficacy of Minocycline for Patients with MSA‐P</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Minocycline 1‐year therapy in multiple‐system‐atrophy: Effect on clinical symptoms and [</title></titleInfo><name type="personal"><namePart type="given">Richard</namePart><namePart type="family">Dodel</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Philipps‐University of Marburg, Germany</affiliation><affiliation>Department of Neurology, University of Bonn, Germany</affiliation><description>Richard Dodel, Annika Spottke, Alexander Gerhard, Alexander Reuss, Wolfgang H. Oertel, and Karla Eggert contributed equally to this work.</description><description>Correspondence: Department of Neurology, Philipps‐University Marburg, Rudolf‐Bultmannstr. 8, 35039 Marburg, Germany</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Annika</namePart><namePart type="family">Spottke</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University of Bonn, Germany</affiliation><description>Richard Dodel, Annika Spottke, Alexander Gerhard, Alexander Reuss, Wolfgang H. Oertel, and Karla Eggert contributed equally to this work.</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Alexander</namePart><namePart type="family">Gerhard</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Wolfson Molecular Imaging Centre, The University of Manchester, United Kingdom</affiliation><affiliation>IMRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College; London, United Kingdom</affiliation><description>Richard Dodel, Annika Spottke, Alexander Gerhard, Alexander Reuss, Wolfgang H. Oertel, and Karla Eggert contributed equally to this work.</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Alexander</namePart><namePart type="family">Reuss</namePart><namePart type="termsOfAddress">MSc</namePart><affiliation>Coordinating Center for Clinical Trials, Philipps‐University of Marburg, Germany</affiliation><description>Richard Dodel, Annika Spottke, Alexander Gerhard, Alexander Reuss, Wolfgang H. Oertel, and Karla Eggert contributed equally to this work.</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Sylvia</namePart><namePart type="family">Reinecker</namePart><namePart type="termsOfAddress">MSc</namePart><affiliation>Coordinating Center for Clinical Trials, Philipps‐University of Marburg, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Nicole</namePart><namePart type="family">Schimke</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Philipps‐University of Marburg, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Claudia</namePart><namePart type="family">Trenkwalder</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Paracelsus‐Elena‐Clinic Kassel, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Friederike</namePart><namePart type="family">Sixel‐Döring</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Paracelsus‐Elena‐Clinic Kassel, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Birgit</namePart><namePart type="family">Herting</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Dresden University of Technology, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Christoph</namePart><namePart type="family">Kamm</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Hertie‐Institute, University of Tübingen, Germany</affiliation><affiliation>Department of Neurology, University of Rostock, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Thomas</namePart><namePart type="family">Gasser</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Hertie‐Institute, University of Tübingen, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Martin</namePart><namePart type="family">Sawires</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Medical University of Innsbruck, Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Felix</namePart><namePart type="family">Geser</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Neurology, Medical University of Innsbruck, Austria</affiliation><affiliation>European MSA Study Group, Innsbruck Medical University, Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Martin</namePart><namePart type="family">Köllensperger</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Medical University of Innsbruck, Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Klaus</namePart><namePart type="family">Seppi</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Medical University of Innsbruck, Austria</affiliation><affiliation>European MSA Study Group, Innsbruck Medical University, Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Manja</namePart><namePart type="family">Kloss</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University of Heidelberg, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Martin</namePart><namePart type="family">Krause</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University of Heidelberg, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Christine</namePart><namePart type="family">Daniels</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University of Kiel, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Günther</namePart><namePart type="family">Deuschl</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University of Kiel, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Silke</namePart><namePart type="family">Böttger</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University of Würzburg, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Markus</namePart><namePart type="family">Naumann</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University of Würzburg, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Axel</namePart><namePart type="family">Lipp</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Wolfson Molecular Imaging Centre, The University of Manchester, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Doreen</namePart><namePart type="family">Gruber</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University of Berlin, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Andreas</namePart><namePart type="family">Kupsch</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Neurology, University of Berlin, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Yansheng</namePart><namePart type="family">Du</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Neurology, Indiana University Medical School, Indianapolis, Indiana, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Federico</namePart><namePart type="family">Turkheimer</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>IMRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College; London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">David J.</namePart><namePart type="family">Brooks</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>IMRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College; London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Thomas</namePart><namePart type="family">Klockgether</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University of Bonn, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Werner</namePart><namePart type="family">Poewe</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Medical University of Innsbruck, Austria</affiliation><affiliation>European MSA Study Group, Innsbruck Medical University, Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Gregor</namePart><namePart type="family">Wenning</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Neurology, Medical University of Innsbruck, Austria</affiliation><affiliation>European MSA Study Group, Innsbruck Medical University, Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Carmen</namePart><namePart type="family">Schade‐Brittinger</namePart><namePart type="termsOfAddress">, MSc</namePart><affiliation>Coordinating Center for Clinical Trials, Philipps‐University of Marburg, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Wolfgang H.</namePart><namePart type="family">Oertel</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Philipps‐University of Marburg, Germany</affiliation><affiliation>Competence Network Parkinson‐Syndrome, Philipps‐University of Marburg, Germany</affiliation><description>Richard Dodel, Annika Spottke, Alexander Gerhard, Alexander Reuss, Wolfgang H. Oertel, and Karla Eggert contributed equally to this work.</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Karla</namePart><namePart type="family">Eggert</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Philipps‐University of Marburg, Germany</affiliation><affiliation>Competence Network Parkinson‐Syndrome, Philipps‐University of Marburg, Germany</affiliation><description>Richard Dodel, Annika Spottke, Alexander Gerhard, Alexander Reuss, Wolfgang H. Oertel, and Karla Eggert contributed equally to this work.</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2010-01-15</dateIssued><dateCaptured encoding="w3cdtf">2008-01-23</dateCaptured><dateValid encoding="w3cdtf">2009-07-08</dateValid><copyrightDate encoding="w3cdtf">2010</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">2</extent><extent unit="tables">3</extent><extent unit="references">44</extent><extent unit="words">8348</extent></physicalDescription><abstract lang="en">The aim of the study was to investigate the efficacy of the antibiotic minocycline as a drug treatment in patients with Multiple‐System‐Atrophy Parkinson‐type (MSA‐P). Sixty‐three patients were randomized to minocycline 200 mg/d (n = 32) or a matching placebo (n = 31). The primary outcome variable was the change in the value of the motor score of the Unified Multiple‐System‐Atrophy Rating‐Scale (UMSARSII) from baseline to 48 weeks. Secondary outcome variables included subscores and individual Parkinsonian symptoms as determined by the UMSARS and the Unified‐Parkinson's‐Disease Rating‐Scale (UPDRS). Health‐related quality of life (HrQoL) was assessed using the EQ‐5D and SF‐12. “Progression rate” was assumed to be reflected in the change in motor function over 48 weeks. At 24 weeks and 48 weeks of follow‐up, there was a significant deterioration in motor scores in both groups, but neither the change in UMSARSII nor in UPDRSIII differed significantly between treatment groups, i.e. “progression rate” was considered to be similar in both treatment arms. HrQoL did not differ among the two treatment arms. In a small subgroup of patients (n = 8; minocycline = 3, placebo = 5)[11C](R)‐PK11195‐PET was performed. The three patients in the minocycline group had an attenuated mean increase in microglial activation as compared to the placebo group (P = 0.07) and in two of them individually showed decreased [11C](R)‐PK11195 binding actually decreased. These preliminary PET‐data suggest that minocycline may interfere with microglial activation. The relevance of this observation requires further investigation. This prospective, 48 week, randomized, double‐blind, multinational study failed to show a clinical effect of minocycline on symptom severity as assessed by clinical motor function. © 2009 Movement Disorder Society</abstract><note type="content">*Potential conflict of interest: The authors report no conflicts of interest and have no financial disclosures to make in respect to this article.</note><note type="funding">German Ministry of Education and Research - No. BMBF Nr. 01GI9901; No. 01GI0201; No. 01GI040; </note><note type="funding">European MSA Study Group</note><note type="funding">Willy Robert Pitzer foundation - No. 16/03; No. PDS UK MAP; No. 02/04; </note><subject lang="en"><genre>Keywords</genre><topic>multiple system atrophy</topic><topic>minocycline</topic><topic>PET</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>97</start><end>107</end><total>11</total></extent></part></relatedItem><identifier type="istex">7E3C331E554F887479122609783881EAE1EEE31D</identifier><identifier type="DOI">10.1002/mds.22732</identifier><identifier type="ArticleID">MDS22732</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2009 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E63 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000E63 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:7E3C331E554F887479122609783881EAE1EEE31D
|texte= Minocycline 1‐year therapy in multiple‐system‐atrophy: Effect on clinical symptoms and [11C] (R)‐PK11195 PET (MEMSA‐trial)
}}
| This area was generated with Dilib version V0.6.23. |  |